Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter A Crooks

Showing results (181-190 of 319) with videos related to

Pageof 32
Sort By:
Neuroscience Letters|March 1, 2018
Pinprick hypo- and hyperalgesia in diabetic rats: Can diet content affect experimental outcome?Jai Shankar K Yadlapalli, Navdeep Dogra, Anqi W Walbaum, et al.
Journal of Pharmaceutical Sciences|March 1, 2005
Bioconversion of naltrexone and its 3-O-alkyl-ester prodrugs in a human skin equivalentDana C Hammell, Elzbieta I Stolarczyk, Mitch Klausner, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 4, 2004
Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transportersDennis K Miller, Peter A Crooks, Guangrong Zheng, et al.
Biochemical Pharmacology|June 16, 2009
Nicotinic receptor-based therapeutics and candidates for smoking cessationLinda P Dwoskin, Andrew M Smith, Thomas E Wooters, et al.
Biochemical Pharmacology|July 28, 2009
The novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), inhibits nicotine-evoked [(3)H]norepinephrine overflow from rat hippocampal slicesAndrew M Smith, Gurpreet K Dhawan, Zhenfa Zhang, et al.
Journal of Pharmaceutical Sciences|October 31, 2008
Human skin permeation of 3-O-alkyl carbamate prodrugs of naltrexoneHaranath K Vaddi, Stan L Banks, Jianhong Chen, et al.
Bioorganic & Medicinal Chemistry Letters|December 17, 2009
Novel substituted (Z)-5-((N-benzyl-1H-indol-3-yl)methylene)imidazolidine-2,4-diones and 5-((N-benzyl-1H-indol-3-yl)methylene)pyrimidine-2,4,6(1H,3H,5H)-triones as potent radio-sensitizing agentsY Thirupathi Reddy, Konjeti R Sekhar, Nidhish Sasi, et al.
Psychopharmacology|May 29, 2012
The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in ratsKristin M Alvers, Joshua S Beckmann, Guangrong Zheng, et al.
Pharmacology, Biochemistry, and Behavior|July 1, 2008
Effects of norketamine enantiomers in rodent models of persistent painJoseph R Holtman, Peter A Crooks, Jaime K Johnson-Hardy, et al.
Molecular Cancer Therapeutics|June 3, 2010
The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomibElisabeth J Walsby, Guy Pratt, Saman Hewamana, et al.
Pageof 32

Showing results (181-190 of 319) with videos related to

Sort By:
Pageof 32
Neuroscience Letters|March 1, 2018
Pinprick hypo- and hyperalgesia in diabetic rats: Can diet content affect experimental outcome?Jai Shankar K Yadlapalli, Navdeep Dogra, Anqi W Walbaum, et al.
Journal of Pharmaceutical Sciences|March 1, 2005
Bioconversion of naltrexone and its 3-O-alkyl-ester prodrugs in a human skin equivalentDana C Hammell, Elzbieta I Stolarczyk, Mitch Klausner, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 4, 2004
Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transportersDennis K Miller, Peter A Crooks, Guangrong Zheng, et al.
Biochemical Pharmacology|June 16, 2009
Nicotinic receptor-based therapeutics and candidates for smoking cessationLinda P Dwoskin, Andrew M Smith, Thomas E Wooters, et al.
Biochemical Pharmacology|July 28, 2009
The novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), inhibits nicotine-evoked [(3)H]norepinephrine overflow from rat hippocampal slicesAndrew M Smith, Gurpreet K Dhawan, Zhenfa Zhang, et al.
Journal of Pharmaceutical Sciences|October 31, 2008
Human skin permeation of 3-O-alkyl carbamate prodrugs of naltrexoneHaranath K Vaddi, Stan L Banks, Jianhong Chen, et al.
Bioorganic & Medicinal Chemistry Letters|December 17, 2009
Novel substituted (Z)-5-((N-benzyl-1H-indol-3-yl)methylene)imidazolidine-2,4-diones and 5-((N-benzyl-1H-indol-3-yl)methylene)pyrimidine-2,4,6(1H,3H,5H)-triones as potent radio-sensitizing agentsY Thirupathi Reddy, Konjeti R Sekhar, Nidhish Sasi, et al.
Psychopharmacology|May 29, 2012
The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in ratsKristin M Alvers, Joshua S Beckmann, Guangrong Zheng, et al.
Pharmacology, Biochemistry, and Behavior|July 1, 2008
Effects of norketamine enantiomers in rodent models of persistent painJoseph R Holtman, Peter A Crooks, Jaime K Johnson-Hardy, et al.
Molecular Cancer Therapeutics|June 3, 2010
The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomibElisabeth J Walsby, Guy Pratt, Saman Hewamana, et al.
Pageof 32